Autoimmune Diseases  >>  prezalumab (AMG 557)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
prezalumab (AMG 557) / Amgen, AstraZeneca
NCT02334306 / 2014-003896-41: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

Hourglass Nov 2018 - Dec 2018 : In Sjögren's syndrome
Hourglass Jan 2017 - Dec 2017 : Completion of enrollment in P2a trial in Sjögren's syndrome
Completed
2a
32
US, Europe
AMG 557/MEDI5872, Placebo
MedImmune LLC, Amgen
Primary Sjögren's Syndrome
01/18
08/18

Download Options